Comparison
Retatrutide vs. Semax
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
2381089-83-2
80714-61-0
Molecular weight
4731.6 g/mol
813.92 g/mol
Half-life
144 h
0.3 h
Sequence
Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSMet-Glu-His-Phe-Pro-Gly-ProMechanism of action
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
4
of which in humans
4
2
Effects recorded
4
3
Open conflicts
0
0
Documented adverse events
2
1